Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria include:~1. Males and females ≥18 years of age~2. Participants with IDA defined as having:~   1. Hemoglobin \<10.0 g/deciliter (dL)~  2. Transferrin saturation \<20%~3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used~4. Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study~Key Exclusion Criteria include:~1. History of allergy to IV iron~2. Allergy to two or more classes of drugs~3. Participants on dialysis or with an estimated glomerular filtration rate \<30 mL/minute/1.73 m\^2~4. Female participants who are pregnant, intend to become pregnant, are breastfeeding, within 2 weeks postpartum, or have a positive serum/urine pregnancy test~5. Hemoglobin ≤7.0 g/dL~6. Serum ferritin \>600 nanograms/mL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).